Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice
- Authors
- Krackhardt F.; Kočka V.; Waliszewski M.; Toušek P.; Janek B.; Trenčan M.; Krajči P.; Lozano F.; Roman K.G.-S.; Otaegui I.; Del Blanco B.G.; Del Olmo V.V.; Nofrerías E.F.; Wachowiak L.; Heang T.M.; Ahn T.H.; Jeong M.H.; Jung B.-C.; Han K.-R.; Piot C.; Sebagh L.; Rischner J.; Pansieri M.; Leschke M.; Rosa S.D.
- Issue Date
- Feb-2020
- Publisher
- Lippincott Williams and Wilkins
- Keywords
- in-stent restenosis; MACE left main coronary artery; polymer-free; real-world patients; sirolimus; TLR; unselected patients; venous bypass
- Citation
- Medicine (United States), v.99, no.8
- Journal Title
- Medicine (United States)
- Volume
- 99
- Number
- 8
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/26321
- DOI
- 10.1097/MD.0000000000019119
- ISSN
- 0025-7974
- Abstract
- Stent designs with ultrathin struts may further increase the procedural success of challenging lesion subsets. The objective of this study was to assess the safety and efficacy of ultrathin strut, polymer-free sirolimus eluting stent (PF-SES) implantations in a large scale, unselected patient population.Adult patients underwent percutaneous coronary interventions (PCI) with a thin-strut PF-SES. Data from two all-comers observational studies having the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled. The accumulated target lesion revascularization (TLR) rate at 9-12 months was the primary endpoint. All dual antiplatelet therapy strategies according to the applicable guidelines were permissible.In total, 7243 patients were prospectively enrolled for PCI with PF-SES in stable coronary artery disease or acute coronary syndrome (ACS). Major risk factors in the overall cohort were diabetes (37.3%), ST elevation myocardial infarction (18.1%) and non-ST myocardial infarction (24.6%). The follow-up rate was 88.6% in the overall population. The TLR rate in the overall cohort was 2.2% whereas definite/probable stent thrombosis (ST) occurred in 0.7%. In patients with in-stent restenosis lesions, the major adverse cardiac events rate was 6.4% whereas the corresponding rate for isolated left main coronary artery (LMCA) disease was highest with 6.7% followed by patients with culprit lesions in vein bypasses (VB, 7.1%). The mortality rate in patients treated in VB lesions was highest with 5.4%, followed by the isolated LMCA subgroup (3.4%) and ACS (2.6%).PCI with PF-SES in an unselected patient population, is associated with low clinical event and ST rates. Furthermore, PF-SES angioplasty in niche indications demonstrated favorable safety and efficacy outcomes with high procedural success rates. © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.